Bill Jackson

Background

Bill Jackson brings to Vector over 25 years of medical device industry experience as an entrepreneur and C-suite executive specializing in building, growing, and successfully exiting healthcare businesses.

Career History

• Co-founder of Preferred Medical Products, a company that was sold to Ballard Medical, a Tyco company
• Worked for medical device leaders Karl Stortz and Stryker, where he was a top producer for both companies
• Co-founded Covalon Technologies, a spinoff from the University of Toronto, and listed on TSXV
• Co-founded Synergist, a medical robotics company that subsequently became Titan Medical, listed on the TSXV
• Co-founder of Attwill Medical Solutions and CEO of its parent company, Attwill Vascular Technologies, a leader in the US contract lyophilization business
• Chief Executive Officer of Vector Science & Therapeutics Corp., which completed its TSX Venture Exchange listing in April 2026

Current Role & Achievements

As CEO of Vector, Jackson has overseen key strategic partnerships, including a three-year development and manufacturing agreement with MPP Group LLC entered in May 2026, securing access to FDA-registered, cGMP facilities for pharmaceutical-grade peptide development. Under Jackson's leadership, Vector expanded its Board of Directors in May 2026 with appointments of Dr. Alexander Dobranowski and Scott Kelly, further strengthening the Company's governance and strategic capabilities.

What Bill Jackson could bring to his role at Vector Science & Therapeutics: Jackson's extensive track record of building and exiting multiple medical device companies positions him to accelerate Vector's commercialization strategy. His experience co-founding multiple TSXV-listed companies (Covalon Technologies, Titan Medical, and now Vector) demonstrates deep expertise in navigating public markets, regulatory pathways, and scaling operations. His background at industry leaders like Stryker and Karl Stortz, combined with his success at Attwill in contract manufacturing and lyophilization services, directly aligns with Vector's need for operational excellence and strategic partnerships in drug delivery and biotech manufacturing as it advances toward commercializing its biomechanical drug delivery platforms.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.